Browsing by Yonsei Author : Rha, Sun Young

eperson profile image
Rha, Sun Young [라선영]
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7006023235)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 530

This table browses all dspace content
Issue DateTitleJournal Title
2024Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinomaBIOORGANIC CHEMISTRY
2024Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 studyLANCET ONCOLOGY
2024Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer ESMO OPEN
2024Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06) BMC CANCER
2024First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer CANCER RESEARCH AND TREATMENT
2024Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer StudyJOURNAL OF CLINICAL ONCOLOGY
2024Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II studyGASTRIC CANCER
2024Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial NATURE COMMUNICATIONS
2023Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialLANCET
2023Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer SCIENTIFIC REPORTS
2023Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialLANCET ONCOLOGY
2023Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response CELL REPORTS MEDICINE
2023Cancer coping self-efficacy, symptoms and their relationship with quality of life among cancer survivorsEUROPEAN JOURNAL OF ONCOLOGY NURSING
2023Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea JOURNAL OF GASTRIC CANCER
2023Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study MOLECULAR CANCER THERAPEUTICS
2023Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trialINTERNATIONAL JOURNAL OF CANCER
2023Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy YONSEI MEDICAL JOURNAL
2023Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms FRONTIERS IN ONCOLOGY
2023Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancerCLINICAL CHEMISTRY AND LABORATORY MEDICINE
2023Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study CANCER RESEARCH AND TREATMENT
2023Care Needs of Adolescents and Young Adults with Cancer Undergoing Active Treatment in South Korea: A Mixed Methods StudyJOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY
2023Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction CancerJOURNAL OF CLINICAL ONCOLOGY
2023Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform ONCOLOGIST
2023PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinomaNATURE CELL BIOLOGY
2023High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma JHEP REPORTS
2023Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20) CANCER RESEARCH AND TREATMENT
2023VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 studyANNALS OF ONCOLOGY
2023Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyLANCET ONCOLOGY
2023Risk factors for delirium among patients with advanced cancer in palliative care: a multicenter, patient-based registry cohort in South Korea EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
2023Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 studyHEPATOLOGY
2023INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) BMC CANCER
2023Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer NEW ENGLAND JOURNAL OF MEDICINE
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2023Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple CombinationJOURNAL OF GASTRIC CANCER
2023Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma ONCOLOGIST
2022Enhanced supportive care for advanced cancer patients: study protocol for a randomized controlled trial BMC NURSING
2022Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion studyLANCET ONCOLOGY
2022Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational BurdenCLINICAL CHEMISTRY
2022Efficacy and safety of pembrolizumab (pembro) monotherapy in East Asian patients (pts) with urothelial carcinoma (UC) in KEYNOTE-045 or KEYNOTE-052ANNALS OF ONCOLOGY
2022Understanding the Social Mechanism of Cancer Misinformation Spread on YouTube and Lessons Learned: Infodemiological Study JOURNAL OF MEDICAL INTERNET RESEARCH
2022A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer NATURE COMMUNICATIONS
2022First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors INVESTIGATIONAL NEW DRUGS
2022Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial EUROPEAN UROLOGY
2022Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancerEUROPEAN JOURNAL OF CANCER
2022Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy CANCERS
2022The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients Genomics & Informatics
2022Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or LeiomyosarcomaCLINICAL CANCER RESEARCH
2022PD-L1 expression and overall survival in Asian and western patients with gastric cancerFUTURE ONCOLOGY
2022Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition GUT
2022Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 studyLANCET ONCOLOGY